Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. 

Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Directorate General operational for Economy, Employment and Research

6K Venture Capital

Smedvig

Ifoghas Investments

Sambrinvest

Merieux Developpement

Meusinvest (Noshaq)

Kenneth Buckfire

Amyl Therapeutics

EnClear Therapies is a company focused on developing therapeutics for neurodegenerative diseases, including ALS.

EnClear Therapies

OptoCeutics is a biopharmaceutical company specializing in therapeutics for neurodegenerative diseases, with a focus on ALS treatment.

OptoCeutics

Denali Therapeutics is a biotechnology company dedicated to developing therapies for neurodegenerative diseases, including ALS.

Denali Therapeutics

Karyopharm Therapeutics is a biopharmaceutical company focused on developing therapies for various diseases, including potential treatments for ALS.

Karyopharm Therapeutics

Vistagen Therapeutics is a biopharmaceutical company engaged in the development of novel therapies for neurological and psychiatric disorders, potentially including ALS.

Vistagen Therapeutics

Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, aiming to improve the lives of patients and their families. The company's lead product candidate is designed to target the underlying causes of motor neuron disease and potentially other neurodegenerative conditions.

Amylyx Pharmaceuticals

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 15, 2024 12:05 PM	89bb8b21
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	72a7ed44
crunchbase profile	general
li profile	general	May 15, 2024 12:05 PM	23a46c7a
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AMYLTX

Amylyx Pharmaceuticals